Jasper Therapeutics targets on facilitating safer learning and therapeutic agents that increase the applying of curative organic process somatic cell transplants and gene therapies.
FREMONT, CA: Jasper Therapeutics Inc., a new set-up in the field of biotechnology, announced the launch of the company with $35 million total Series A financing. Jasper Therapeutics targets on facilitating safer learning and therapeutic agents that increase the applying of curative organic process somatic cell transplants and gene therapies.
Among others, the lead investors were Qiming Venture Partners USA and Abingworth LLP, with further investment from Surveyor Capital (a Citadel company) and contributions from Alexandria Venture Investments, LLC. The newly invested finance will be used to take forward the clinical development of the company's main product profile, JSP191, which is designed to substitute or reduce the toxicity of chemotherapy and radiation therapy as a habituation regimen to prepare patients for hematopoietic cell transplant.
The development of Jasper's JSP191 is additionally supported by association with the CA Institute for Regenerative medication (CIRM), which has been supporting the program and is committed to providing a total of $23 million in grant support. Amgen, which discovered JSP191 (previously AMG191), has licensed international rights to Jasper as part of the Series A financing, also consists of translational science and materials from Stanford University.
"Stem cell transplantation is a potentially curative therapy for people with hematologic cancers, autoimmune diseases, and debilitating genetic diseases. However, the pre-transplant conditioning required to prepare patients for transplant involves highly toxic chemotherapy, which can be life-threatening and limits the number of people who are able to benefit," said Dr. Shizuru, co-founder, and member of the Board of Directors of Jasper Therapeutics. "JSP191 is the only anti-CD117 antibody to demonstrate safety and efficacy in severely ill patients receiving stem cell transplant in the clinic. We plan to expand clinical development to patients receiving transplants for acute myeloid leukemia/ myelodysplastic syndrome or autoimmune diseases and to patients receiving stem cell-directed gene therapies."
Jasper was co-founded by Susan Prohaska, Ph.D., a Stanford University-trained immunologist, stem cell biologist and first-stage drug development professional, and Judith Shizuru, M.D., Ph.D., a hematopoietic stem cell transplant specialist at Stanford University.
Currently, the JSP191 is being evaluated in part one test as a learning agent to support somatic cell transplantation in patients with severe combined immunological disorder (SCID) who acknowledged a prior stem cell transplant that failed.